Tipiracil clinical trials
Its developmentBy Simcere Pharmaceutical Group, step by step1 company-led study, furthest phase 3: when each phase was reached, its deals, target and what is ahead.Counted the way a researcher would: Tipiracil with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses tipiracil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tipiracil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 25 Apr 2016 · Lonsurf · EMEA/H/C/003897 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Institut de Recherches Internationales Servier (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Sun Yat-sen University (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Often tested with
Tested in the same studies.
Trifluridine (6) · HMPL-013 (2) · Bemarituzumab (1) · Paclitaxel (1) · Ramucirumab (1) · Irinotecan (1) · Bevacizumab (1) · Suvemcitug (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tipiracil.
Studies
Open first, then newest update. How each study uses tipiracil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07361003Written as Suvemcitug injection, trifluridine/tipiracil tabletsHow we know
- Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07286695Written as Fruquintinib Combined With trifluridine/tipiracilHow we know
- Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07261709Written as Trifluridine/tipiracil plus fruquintinibHow we know
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06992648Written as Trifluridine/Tipiracil + RegorafenibHow we know
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyCompletedPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06680622Written as bemarituzumab, trifluridine/tipiracilHow we know
- A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyCompletedPhase 2Institut de Recherches Internationales ServierNCT02743221Written as Trifluridine/tipiracil + bevacizumabHow we know
Given beside what is tested · 4 — tipiracil is usual care or a partner of the new treatment
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasRecruitingPhase 1Inhibrx Biosciences, IncNCT03715933Written as Trifluridine + TipiracilHow we know
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedPhase 2M.D. Anderson Cancer CenterNCT07011550Written as Trifluridine + TipiracilHow we know
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminatedPhase 1Astellas Pharma Global Development, Inc.NCT05083481Written as Trifluridine + TipiracilHow we know
- Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineActive, not recruitingPhase 1/2Centre Georges Francois LeclercNCT05201352Written as trifluridine/tipiracil + XB2001How we know
As the comparator · 1 — what is tested is compared with tipiracil
Codes
What other systems call tipiracil · ClinicalTrials.gg INT000590
- MeSH (NLM) C000613754tipiracilOne source NLM
- UNII (FDA) NGO10K751PTIPIRACILConfirmed FDA, NLM, Wikidata
- RxNorm 1670304Confirmed FDA, Wikidata
- Wikidata Q21098889tipiracilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152646TipiracilOne source FDA
- DrugBank DB09343One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613754 | tipiracil | One source NLM |
| UNII (FDA) | NGO10K751P | TIPIRACIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1670304 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21098889 | tipiracil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152646 | Tipiracil | One source FDA |
| DrugBank | DB09343 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.